Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...

The reduction of hematocrit below 45% is a primary treatment ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.

The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those who received placebo ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV ... in 293 PV patients with uncontrolled hematocrit who are phelobotomy-dependent ...

Many patients with polycythemia vera, the news release noted ... undergo phlebotomy — described as a process of removing blood to manage elevated levels of hematocrit, or the percentage of red blood ...

The reduction of hematocrit below 45% is a primary treatment goal for ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The trial is ...

Rusfertide is designed to treat polycythemia vera, a cancer in which red blood cells ... Treatment was also associated with improved hematocrit control and better patient-reported outcomes. No new ...